William Duke Sells 19,663 Shares of Invivyd (NASDAQ:IVVD) Stock

Invivyd, Inc. (NASDAQ:IVVD) CFO William Duke sold 19,663 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $1.54, for a total value of $30,281.02. Following the transaction, the chief financial officer owned 128,681 shares of the company’s stock, valued at $198,168.74. This represents a 13.26% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Invivyd Stock Performance

Shares of IVVD traded up $0.10 during mid-day trading on Wednesday, hitting $1.65. 1,468,415 shares of the stock were exchanged, compared to its average volume of 3,015,442. The company has a market cap of $384.65 million, a PE ratio of -3.51 and a beta of 0.60. Invivyd, Inc. has a 52-week low of $0.46 and a 52-week high of $3.07. The firm has a 50-day moving average of $2.19 and a two-hundred day moving average of $1.75.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Invivyd in a research note on Monday, December 29th. BTIG Research reissued a “buy” rating on shares of Invivyd in a research note on Wednesday, January 21st. HC Wainwright upped their price objective on Invivyd from $5.00 to $10.00 and gave the company a “buy” rating in a research report on Friday, October 31st. D. Boral Capital reiterated a “hold” rating on shares of Invivyd in a report on Tuesday, November 25th. Finally, Zacks Research raised Invivyd from a “strong sell” rating to a “hold” rating in a research report on Thursday, November 13th. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $8.00.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of IVVD. Courier Capital LLC purchased a new stake in shares of Invivyd in the fourth quarter worth approximately $25,000. Bronte Capital Management Pty Ltd. purchased a new stake in Invivyd in the fourth quarter worth $27,000. Catalyst Funds Management Pty Ltd purchased a new stake in Invivyd in the second quarter worth $27,000. DRW Securities LLC purchased a new stake in shares of Invivyd during the fourth quarter valued at $27,000. Finally, Vanguard Personalized Indexing Management LLC grew its holdings in shares of Invivyd by 238.6% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 39,941 shares of the company’s stock worth $29,000 after purchasing an additional 28,146 shares during the last quarter. Institutional investors own 70.36% of the company’s stock.

Invivyd News Summary

Here are the key news stories impacting Invivyd this week:

• Neutral Sentiment: Multiple Form 4 filings disclose open‑market sales (no new corporate/clinical announcements). The disclosures are routine SEC insider-sale filings rather than earnings or clinical-data releases. Representative SEC Filing
• Neutral Sentiment: Aggregate size and liquidity context — filings show insiders sold a total of over ~220,000 shares across Feb. 17–18 (multiple executives, see items below). Today’s volume (≈1.47M) is below the stock’s 3M average, which can amplify price moves on relatively modest buying or selling flows.
• Negative Sentiment: Jill Andersen — sold 32,771 shares on 2/17 at ~$1.54 and 34,939 shares on 2/18 at ~$1.58; filings show a double‑digit percentage reduction in her holdings. SEC Filing – Jill Andersen
• Negative Sentiment: Timothy Edward Lee — sold 19,663 shares on 2/17 at ~$1.54 and 20,964 on 2/18 at ~$1.58; each sale reduced his ownership by ~12–15%. SEC Filing – Timothy Lee
• Negative Sentiment: William E. Duke (CFO) — sold 19,663 shares on 2/17 at ~$1.54 and 20,964 on 2/18 at ~$1.58; filings show ~13–16% reductions in his holdings. SEC Filing – William Duke
• Negative Sentiment: Julie Green — sold 19,663 shares on 2/17 at ~$1.54 and 20,964 on 2/18 at ~$1.58; each sale trimmed her stake by ~13–16%. SEC Filing – Julie Green
• Negative Sentiment: Robert D. Allen III — sold 18,189 shares on 2/17 at ~$1.54 and 19,392 on 2/18 at ~$1.58; filings show ~12–14% reductions in his holdings. SEC Filing – Robert Allen

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.